Mereo BioPharma Group PLCNASDAQ:MREO
- LAST PRICE3.0400
- TODAY'S CHANGE (%)-0.2200 (-6.7485%)
- Bid / Lots3.0400/ 5
- Ask / Lots3.0700/ 10
- Open / Previous Close3.2500 / 3.2600
- Day Range
- 52 Week Range
- Volume506,548
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MREO |
|---|---|---|
| 09:32 ET | 1288 | 3.26 |
| 09:38 ET | 100 | 3.27 |
| 09:39 ET | 100 | 3.27 |
| 09:41 ET | 10500 | 3.24 |
| 09:43 ET | 100 | 3.26 |
| 09:45 ET | 1800 | 3.27 |
| 09:50 ET | 900 | 3.265 |
| 09:52 ET | 100 | 3.262 |
| 09:54 ET | 1200 | 3.27 |
| 09:56 ET | 100 | 3.27 |
| 09:57 ET | 1300 | 3.2775 |
| 09:59 ET | 17277 | 3.31 |
| 10:01 ET | 900 | 3.31 |
| 10:03 ET | 7615 | 3.2935 |
| 10:06 ET | 100 | 3.3099 |
| 10:14 ET | 1104 | 3.3 |
| 10:15 ET | 810 | 3.305 |
| 10:19 ET | 3599 | 3.3 |
| 10:21 ET | 600 | 3.3 |
| 10:24 ET | 1930 | 3.3 |
| 10:26 ET | 11002 | 3.3 |
| 10:28 ET | 5775 | 3.29 |
| 10:30 ET | 300 | 3.295 |
| 10:32 ET | 500 | 3.3 |
| 10:33 ET | 100 | 3.3 |
| 10:35 ET | 100 | 3.3 |
| 10:37 ET | 35369 | 3.265 |
| 10:39 ET | 7416 | 3.26 |
| 10:42 ET | 1100 | 3.255 |
| 10:44 ET | 100 | 3.24 |
| 10:46 ET | 3403 | 3.215 |
| 10:48 ET | 2100 | 3.225 |
| 10:50 ET | 2294 | 3.205 |
| 10:51 ET | 4200 | 3.205 |
| 10:53 ET | 8772 | 3.23 |
| 10:55 ET | 500 | 3.225 |
| 11:00 ET | 100 | 3.225 |
| 11:02 ET | 300 | 3.225 |
| 11:04 ET | 3000 | 3.225 |
| 11:06 ET | 1450 | 3.2298 |
| 11:08 ET | 11229 | 3.19 |
| 11:09 ET | 32994 | 3.19 |
| 11:11 ET | 400 | 3.185 |
| 11:13 ET | 1264 | 3.1749 |
| 11:15 ET | 700 | 3.185 |
| 11:18 ET | 2300 | 3.18 |
| 11:20 ET | 13594 | 3.1599 |
| 11:22 ET | 500 | 3.155 |
| 11:24 ET | 1500 | 3.1501 |
| 11:27 ET | 1959 | 3.1499 |
| 11:29 ET | 13505 | 3.15 |
| 11:31 ET | 400 | 3.145 |
| 11:36 ET | 1900 | 3.15 |
| 11:38 ET | 4494 | 3.1399 |
| 11:40 ET | 600 | 3.13 |
| 11:42 ET | 1415 | 3.12 |
| 11:44 ET | 628 | 3.12 |
| 11:45 ET | 300 | 3.12 |
| 11:47 ET | 5449 | 3.125 |
| 11:49 ET | 1500 | 3.12 |
| 11:51 ET | 600 | 3.125 |
| 11:54 ET | 363 | 3.11 |
| 12:00 ET | 8634 | 3.115 |
| 12:05 ET | 14337 | 3.085 |
| 12:07 ET | 133 | 3.08 |
| 12:12 ET | 2717 | 3.105 |
| 12:14 ET | 300 | 3.1098 |
| 12:16 ET | 300 | 3.105 |
| 12:18 ET | 4400 | 3.0999 |
| 12:21 ET | 600 | 3.095 |
| 12:23 ET | 1072 | 3.08 |
| 12:25 ET | 100 | 3.09 |
| 12:27 ET | 200 | 3.08 |
| 12:30 ET | 1000 | 3.1 |
| 12:34 ET | 1000 | 3.1 |
| 12:38 ET | 643 | 3.1035 |
| 12:43 ET | 16476 | 3.14 |
| 12:45 ET | 500 | 3.11 |
| 12:48 ET | 800 | 3.1 |
| 12:52 ET | 200 | 3.1 |
| 12:54 ET | 575 | 3.1 |
| 12:56 ET | 254 | 3.11 |
| 12:57 ET | 1509 | 3.11 |
| 12:59 ET | 100 | 3.11 |
| 01:03 ET | 1006 | 3.1093 |
| 01:06 ET | 450 | 3.1045 |
| 01:10 ET | 4776 | 3.0999 |
| 01:12 ET | 200 | 3.0999 |
| 01:14 ET | 400 | 3.09 |
| 01:15 ET | 2502 | 3.0999 |
| 01:17 ET | 800 | 3.1 |
| 01:19 ET | 325 | 3.105 |
| 01:21 ET | 300 | 3.1 |
| 01:24 ET | 6389 | 3.101 |
| 01:26 ET | 400 | 3.1058 |
| 01:28 ET | 920 | 3.105 |
| 01:30 ET | 500 | 3.1 |
| 01:32 ET | 600 | 3.1 |
| 01:33 ET | 100 | 3.1 |
| 01:35 ET | 1000 | 3.1093 |
| 01:37 ET | 8399 | 3.115 |
| 01:42 ET | 800 | 3.1 |
| 01:44 ET | 500 | 3.1 |
| 01:46 ET | 622 | 3.1 |
| 01:50 ET | 293 | 3.105 |
| 01:51 ET | 3852 | 3.125 |
| 01:53 ET | 358 | 3.12 |
| 01:57 ET | 500 | 3.11 |
| 02:00 ET | 1752 | 3.12 |
| 02:02 ET | 400 | 3.12 |
| 02:04 ET | 100 | 3.12 |
| 02:08 ET | 300 | 3.11 |
| 02:09 ET | 2000 | 3.114 |
| 02:11 ET | 500 | 3.115 |
| 02:13 ET | 3343 | 3.12 |
| 02:15 ET | 1550 | 3.12 |
| 02:18 ET | 970 | 3.13 |
| 02:20 ET | 600 | 3.13 |
| 02:22 ET | 700 | 3.13 |
| 02:24 ET | 303 | 3.13 |
| 02:26 ET | 1400 | 3.13 |
| 02:27 ET | 711 | 3.12 |
| 02:33 ET | 100 | 3.12 |
| 02:40 ET | 222 | 3.12 |
| 02:42 ET | 5917 | 3.12 |
| 02:44 ET | 200 | 3.12 |
| 02:47 ET | 11548 | 3.115 |
| 02:49 ET | 4151 | 3.12 |
| 02:51 ET | 1061 | 3.12 |
| 02:56 ET | 237 | 3.12 |
| 02:58 ET | 495 | 3.12 |
| 03:00 ET | 1276 | 3.12 |
| 03:02 ET | 2156 | 3.12 |
| 03:03 ET | 952 | 3.12 |
| 03:05 ET | 1047 | 3.11 |
| 03:07 ET | 2373 | 3.12 |
| 03:09 ET | 2585 | 3.1204 |
| 03:12 ET | 220 | 3.12 |
| 03:14 ET | 334 | 3.12 |
| 03:16 ET | 2822 | 3.13 |
| 03:18 ET | 1691 | 3.12 |
| 03:20 ET | 100 | 3.11 |
| 03:23 ET | 100 | 3.1199 |
| 03:25 ET | 100 | 3.119 |
| 03:27 ET | 200 | 3.115 |
| 03:30 ET | 4687 | 3.1199 |
| 03:32 ET | 400 | 3.11 |
| 03:34 ET | 500 | 3.11 |
| 03:36 ET | 9598 | 3.0899 |
| 03:38 ET | 6539 | 3.06 |
| 03:39 ET | 9306 | 3.04 |
| 03:41 ET | 6324 | 3.0371 |
| 03:43 ET | 8600 | 3.025 |
| 03:45 ET | 1629 | 3.03 |
| 03:48 ET | 2968 | 3.045 |
| 03:50 ET | 6028 | 3.045 |
| 03:52 ET | 1150 | 3.055 |
| 03:54 ET | 2854 | 3.055 |
| 03:56 ET | 2380 | 3.05 |
| 03:57 ET | 9192 | 3.045 |
| 03:59 ET | 4153 | 3.04 |
May 16, 2024
DJ Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 11:16AM ET on Thursday May 16, 2024 by Dow Jones
11:16AM ET on Thursday May 16, 2024 by Dow JonesDJ Mereo BioPharma Group Price Target Maintained With a $6.00/Share by Needham, from 7:33AM ET on Thursday May 16, 2024 by Dow Jones
7:33AM ET on Thursday May 16, 2024 by Dow Jones
May 15, 2024
Press Release: Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow JonesMereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 4:01PM ET on Wednesday May 15, 2024 by Dow Jones
4:01PM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mereo BioPharma Group PLC | 457.3M | -11.5x | --- |
Aerovate Therapeutics Inc | 581.1M | -6.5x | --- |
Mind Medicine (MindMed) Inc | 584.0M | -2.8x | --- |
Savara Inc | 576.2M | -11.2x | --- |
Third Harmonic Bio Inc | 586.3M | -20.8x | --- |
Altimmune Inc | 570.1M | -4.8x | --- |
Company Information
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Contact Information
- Headquarters
- One Cavendish Place, Fourth FloorLONDON, United Kingdom W1G0QF
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Michael Wyzga
- Chief Executive Officer, Director
- Denise Scots-Knight
- Chief Financial Officer
- Christine Fox
- Senior Vice President - Clinical Development
- Suba Krishnan
- Senior Vice President - Therapeutic Head
- Jackie Parkin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $457.3M |
|---|---|
Revenue (TTM) | $9.1M |
Shares Outstanding | 140.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-0.27 |
Book Value | $0.63 |
P/E Ratio | -11.5x |
Price/Sales (TTM) | 50.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -444.28% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
